Symptom-based ADHD diagnoses may not align with a patient's underlying neuropathy, making it harder to develop individualized treatment plans. In a new study published in Psychiatry Research, a team led by Yale School of Medicine's Bruce Wexler, MD, identified four ADHD subgroups based on biomarkers observed during digital neurotherapy.